Diagnostic testing for HIV type 1 RNA in seronegative blood

Detlef Ritter, James Taylor, Richard Walkenbach, Michael Creer, Max Q. Arens

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We studied the feasibility of routine diagnostic testing for HIV-1 RNA at a publicly funded testing site. HIV-1 RNA was determined with a commercial polymerase chain reaction assay in pooled seronegative blood samples submitted for HIV testing to a public health laboratory. Recovery of HIV-1 RNA from the samples was estimated as at least 8% of viral RNA that was found in freshly prepared plasma. We estimated that screening for HIV-1 RNA in serum pools would result in the identification of blood specimens from more than 95% of acutely infected patients. The frequency of HIV-1 RNA in seronegative blood samples was estimated to be between 19 and 601 per 106 submitted specimens. The ratio of HIV-1 RNA positive and seronegative samples to specimens with HIV-1 antibodies confirmed by Western blot was estimated to be between 0.2% and 6.6%. The reagent costs for identifying 1 HIV-infected blood sample were 10-fold higher with the commercially available HIV-1 RNA assay compared with the HIV antibody enzyme-linked immunosorbent assay. Diagnostic testing for HIV-1 RNA may be warranted in high-risk populations since acutely infected patients may benefit most from antiretroviral therapy and are thought to contribute disproportionately to the HIV epidemic.

Original languageEnglish (US)
Pages (from-to)128-134
Number of pages7
JournalAmerican Journal of Clinical Pathology
Volume113
Issue number1
StatePublished - 2000

Fingerprint

HIV-1
RNA
HIV Antibodies
HIV
Viral RNA
Public Health
Western Blotting
Enzyme-Linked Immunosorbent Assay
Costs and Cost Analysis
Polymerase Chain Reaction
Serum
Population

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Ritter, D., Taylor, J., Walkenbach, R., Creer, M., & Arens, M. Q. (2000). Diagnostic testing for HIV type 1 RNA in seronegative blood. American Journal of Clinical Pathology, 113(1), 128-134.
Ritter, Detlef ; Taylor, James ; Walkenbach, Richard ; Creer, Michael ; Arens, Max Q. / Diagnostic testing for HIV type 1 RNA in seronegative blood. In: American Journal of Clinical Pathology. 2000 ; Vol. 113, No. 1. pp. 128-134.
@article{1dab7957b97546c0ac0f2571dd94922c,
title = "Diagnostic testing for HIV type 1 RNA in seronegative blood",
abstract = "We studied the feasibility of routine diagnostic testing for HIV-1 RNA at a publicly funded testing site. HIV-1 RNA was determined with a commercial polymerase chain reaction assay in pooled seronegative blood samples submitted for HIV testing to a public health laboratory. Recovery of HIV-1 RNA from the samples was estimated as at least 8{\%} of viral RNA that was found in freshly prepared plasma. We estimated that screening for HIV-1 RNA in serum pools would result in the identification of blood specimens from more than 95{\%} of acutely infected patients. The frequency of HIV-1 RNA in seronegative blood samples was estimated to be between 19 and 601 per 106 submitted specimens. The ratio of HIV-1 RNA positive and seronegative samples to specimens with HIV-1 antibodies confirmed by Western blot was estimated to be between 0.2{\%} and 6.6{\%}. The reagent costs for identifying 1 HIV-infected blood sample were 10-fold higher with the commercially available HIV-1 RNA assay compared with the HIV antibody enzyme-linked immunosorbent assay. Diagnostic testing for HIV-1 RNA may be warranted in high-risk populations since acutely infected patients may benefit most from antiretroviral therapy and are thought to contribute disproportionately to the HIV epidemic.",
author = "Detlef Ritter and James Taylor and Richard Walkenbach and Michael Creer and Arens, {Max Q.}",
year = "2000",
language = "English (US)",
volume = "113",
pages = "128--134",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "1",

}

Ritter, D, Taylor, J, Walkenbach, R, Creer, M & Arens, MQ 2000, 'Diagnostic testing for HIV type 1 RNA in seronegative blood', American Journal of Clinical Pathology, vol. 113, no. 1, pp. 128-134.

Diagnostic testing for HIV type 1 RNA in seronegative blood. / Ritter, Detlef; Taylor, James; Walkenbach, Richard; Creer, Michael; Arens, Max Q.

In: American Journal of Clinical Pathology, Vol. 113, No. 1, 2000, p. 128-134.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Diagnostic testing for HIV type 1 RNA in seronegative blood

AU - Ritter, Detlef

AU - Taylor, James

AU - Walkenbach, Richard

AU - Creer, Michael

AU - Arens, Max Q.

PY - 2000

Y1 - 2000

N2 - We studied the feasibility of routine diagnostic testing for HIV-1 RNA at a publicly funded testing site. HIV-1 RNA was determined with a commercial polymerase chain reaction assay in pooled seronegative blood samples submitted for HIV testing to a public health laboratory. Recovery of HIV-1 RNA from the samples was estimated as at least 8% of viral RNA that was found in freshly prepared plasma. We estimated that screening for HIV-1 RNA in serum pools would result in the identification of blood specimens from more than 95% of acutely infected patients. The frequency of HIV-1 RNA in seronegative blood samples was estimated to be between 19 and 601 per 106 submitted specimens. The ratio of HIV-1 RNA positive and seronegative samples to specimens with HIV-1 antibodies confirmed by Western blot was estimated to be between 0.2% and 6.6%. The reagent costs for identifying 1 HIV-infected blood sample were 10-fold higher with the commercially available HIV-1 RNA assay compared with the HIV antibody enzyme-linked immunosorbent assay. Diagnostic testing for HIV-1 RNA may be warranted in high-risk populations since acutely infected patients may benefit most from antiretroviral therapy and are thought to contribute disproportionately to the HIV epidemic.

AB - We studied the feasibility of routine diagnostic testing for HIV-1 RNA at a publicly funded testing site. HIV-1 RNA was determined with a commercial polymerase chain reaction assay in pooled seronegative blood samples submitted for HIV testing to a public health laboratory. Recovery of HIV-1 RNA from the samples was estimated as at least 8% of viral RNA that was found in freshly prepared plasma. We estimated that screening for HIV-1 RNA in serum pools would result in the identification of blood specimens from more than 95% of acutely infected patients. The frequency of HIV-1 RNA in seronegative blood samples was estimated to be between 19 and 601 per 106 submitted specimens. The ratio of HIV-1 RNA positive and seronegative samples to specimens with HIV-1 antibodies confirmed by Western blot was estimated to be between 0.2% and 6.6%. The reagent costs for identifying 1 HIV-infected blood sample were 10-fold higher with the commercially available HIV-1 RNA assay compared with the HIV antibody enzyme-linked immunosorbent assay. Diagnostic testing for HIV-1 RNA may be warranted in high-risk populations since acutely infected patients may benefit most from antiretroviral therapy and are thought to contribute disproportionately to the HIV epidemic.

UR - http://www.scopus.com/inward/record.url?scp=0034049505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034049505&partnerID=8YFLogxK

M3 - Article

C2 - 10631866

AN - SCOPUS:0034049505

VL - 113

SP - 128

EP - 134

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 1

ER -